Bill > H1254

This bill aims to promote comprehensive transparency in the pharmaceutical industry. The key provisions include: 1. Defining new terms like "early notice," "pharmaceutical manufacturing company," "pharmacy benefit manager," and "pipeline drugs" to clarify the scope of the legislation. 2. Expanding the Health Policy Commission's authority to collect information and testimony from pharmaceutical manufacturing companies and pharmacy benefit managers regarding prescription drug costs, price increases, and other factors impacting costs. 3. Requiring pharmaceutical manufacturing companies to disclose detailed information about drug pricing, including wholesale acquisition cost increases, research and development costs, and other factors when requested by the Commission. 4. Allowing the Commission to identify proposed supplemental rebates for certain drugs and require manufacturers to provide additional justification if their pricing is deemed unreasonable or excessive. 5. Mandating pharmaceutical manufacturers to provide early notice and information about pipeline drugs, generic drugs, and biosimilar drugs that may have a significant impact on state health care expenditures. 6. Expanding the Attorney General's authority to monitor and obtain information related to prescription drug cost and price trends from various entities, including pharmaceutical manufacturing companies and pharmacy benefit managers. 7. Requiring the Center for Health Information and Analysis to analyze and report on pharmaceutical manufacturing company and pharmacy benefit manager data related to drug pricing, formulary designs, and financial incentives. Overall, the bill aims to enhance transparency and oversight of the pharmaceutical industry in Massachusetts to help address rising prescription drug costs.

Health and Social Services

https://malegislature.gov/Bills/192/H1254